PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR EMA Recommends Extension of Indications for Inotuzumab Ozogamicin April 29, 2026 FDA Approves Olutasidenib for Relapsed or Refractory Acute Myeloid Leukaemia with... December 9, 2022 Research with integrity – why building networks is vital for integrity March 22, 2023 A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... December 4, 2019 Load more HOT NEWS Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy The Right to be Forgotten: ESMO Calls on EU Countries to... Merging the Histologic and Molecular Data Into an Integrated Score Significantly...
